Sign in

    Elliott Bosco • UBS Group AG

    Elliott Bosco is an analyst who was previously registered as a broker, with two years of experience in the financial sector as identified through FINRA BrokerCheck. While there is limited detailed public information on his exact title at UBS Group AG or specific coverage specialization, available records do not list current coverage of particular companies or measured performance metrics such as TipRanks rankings or documented investment returns. His FINRA registration (CRD# 7455004) shows no state securities licenses currently active, and no disclosure events. Career timeline details or prior firm history beyond this registration period are not publicly available, and professional credentials are limited to previous broker registration with no current securities licenses.

    Elliott Bosco's questions to Nanobiotix SA (NBTX) leadership

    Elliott Bosco's questions to Nanobiotix SA (NBTX) leadership • FY 2023

    Question

    Elliott Bosco, on behalf of Colin Bristow at UBS, asked about the next steps for the inoperable lung cancer program following the determination of a recommended Phase II dose, and also inquired about what to expect from the initial readout for the Phase Ib/II esophageal cancer study.

    Answer

    CEO Laurent Levy explained that the lung cancer study with MD Anderson is for patients who relapsed after prior radiation, and with the recommended Phase II dose now established, recruitment is progressing well with an update expected soon. For the esophageal cancer trial, which targets patients with non-resectable tumors, he noted that recruitment is ongoing and discussions about potentially reshaping the trial are underway with MD Anderson, with updates anticipated in the coming quarters.

    Ask Fintool Equity Research AI